The Relative Strength (RS) Rating for Takeda Pharmaceutical ADR moved up into a higher percentile Tuesday, as it got a lift from 68 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matched up against all other stocks.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating of above 80 as they begin their biggest price moves. See if Takeda Pharmaceutical ADR can continue to rebound and hit that benchmark.
While Takeda Pharmaceutical ADR is not near a proper buy zone right now, see if it is able to form and break out of a proper base.
Earnings growth dropped in the most recent report from -21% to -33%. But sales moved higher, from -8% to 1%.
The company holds the No. 16 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and AbbVie are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
